Loading market dashboard
Lexeo Therapeutics, Inc. Common Stock
LXEOHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY.
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform to be presented at ASGCT 2026 Appointed Laura Sepp-Lorenzino, Ph.D. to Board of Directors Cash, cash equivalents and investments of $227.6 million expected to provide operational runway into 2028 NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the first quarter 2026.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. “We're excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo's science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich ataxia (FA) to a novel TNNI3 gene therapy program enabled by an innovative and clinically relevant porcine disease model, and an industry-leading, highly optimized AAV manufacturing platform,” said Narinder Bhalla, MD, Chief Medical Officer of Lexeo Therapeutics.
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration Strengthened leadership team with addition of new Chief Medical Officer and senior appointments bolstering cardiac expertise Cash, cash equivalents and investments of $246.6 million expected to provide operational runway into 2028 NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the fourth quarter and full year 2025. “Over the past year we have made meaningful progress across our cardiac pipeline, including significant advancements for both LX2006 and LX2020,” said R.
Shares of Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy
